GH
$157.21
$-2.74 (-1.72%)-1.72%
After HoursLoading chart...
IndexN/A
Market Cap21.10B
Enterprise Value14.14B
Income$-0.10B
Sales$0.20B
EmployeesN/A
P/E-60.93
P/S13.04
P/B-128.95
P/C-54.94
EV/EBITDA-37.81
EV/SalesN/A
EPS (ttm)-2.58
EarningsN/A
Gross Margin64.46%
Oper. Margin-44.53%
Profit Margin-42.39%
Volume2.47M
Shs Outstand0.13B
Change-1.46%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $739.02M | $563.95M | $449.54M | $373.65M | $286.73M | $214.38M | $90.64M | $49.84M |
| Cost of Revenue | $289.80M | $227.05M | $156.32M | $122.91M | $92.53M | $70.72M | $43.21M | $31.62M |
| Gross Profit | $449.22M | $336.90M | $293.21M | $250.74M | $194.19M | $143.66M | $47.43M | $18.22M |
| Gross Margin | 60.79% | 59.74% | 65.23% | 67.11% | 67.73% | 67.01% | 52.33% | 36.56% |
| Operating Expenses | $892.81M | $901.62M | $837.59M | $661.74M | $449.14M | $226.03M | $140.37M | $94.84M |
| Operating Income | $-443.59M | $-564.73M | $-544.38M | $-411.00M | $-254.95M | $-82.37M | $-92.94M | $-76.61M |
| Operating Margin | -60.02% | -100.14% | -121.10% | -110.00% | -88.92% | -38.42% | -102.54% | -153.71% |
| Net Income | $-436.37M | $-479.45M | $-654.59M | $-405.67M | $-253.78M | $-75.65M | $-85.06M | $-83.22M |
| Net Margin | -59.05% | -85.02% | -145.61% | -108.57% | -88.51% | -35.29% | -93.85% | -166.97% |
| EPS (Basic) | $-3.56 | $-4.28 | $-6.41 | $-3.80 | $-2.53 | $-0.75 | $-1.00 | $-1.18 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $1.49B | $1.79B | $1.61B | $2.20B | $2.27B | $962.53M | $587.40M | $342.94M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.63B | $1.63B | $1.55B | $1.56B | $916.19M | $114.54M | $62.45M | $34.33M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $-139.65M | $158.68M | $60.18M | $645.00M | $1.30B | $798.39M | $483.15M | $308.61M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $-139.65M | $158.68M | $60.18M | $645.00M | $1.30B | $798.39M | $483.15M | $308.61M |
| Total Liabilities & Stockholders Equity | $1.49B | $1.79B | $1.61B | $2.20B | $2.27B | $962.53M | $587.40M | $342.94M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-436.37M | $-479.45M | $-654.59M | $-405.67M | $-253.78M | $-75.65M | $-85.06M | $-83.22M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-239.86M | $-324.98M | $-309.46M | $-209.02M | $-103.93M | $-47.13M | $-72.19M | $-72.23M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035GlobeNewswire Inc. Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS InsiderGlobeNewswire Inc. Why Grail Could Be the Sleeper Stock Everyone's About to NoticeThe Motley Fool AI-Powered Imaging Systems and Deep Learning Software Revolutionize Cancer Diagnostics Market GloballyGlobeNewswire Inc. Guardant Health Secures FDA Approval For Expanded Liquid Biopsy TestBenzinga Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsightGlobeNewswire Inc. Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer TherapyBenzinga Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level OutlookGlobeNewswire Inc.
Show 12 more stories
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA FilingsThe Motley Fool FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal CancerBenzinga Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market InsightsGlobeNewswire Inc. Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the LineThe Motley Fool Pre-Dx Oncology Market Outlook 2026–2035: A Strategic Insight by Towards HealthcareGlobeNewswire Inc. Oncology Biomarker Market Accelerates Toward USD 113.5 Billion by 2034GlobeNewswire Inc. Breast Cancer Screening Tests Market to Reach USD 8.77 Billion by 2034, Shows Steady 7.04% CAGRGlobeNewswire Inc. Molecular Diagnostics Market to Grow at 13.1% CAGR Through 2030GlobeNewswire Inc. Global Liquid Biopsy Market Set to Reach USD 7.05 Billion by 2030 | MarketsandMarkets™GlobeNewswire Inc. Guardant Health (GH) Q2 Revenue Up 31%The Motley Fool Minimal Residual Disease Testing Market Trends Analysis Report 2025-2030 | North America Leads in MRD Testing Market with Advanced Reimbursement EcosystemGlobeNewswire Inc. Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry LandscapeGlobeNewswire Inc.
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Discover more
You may be interested in